Detalhe da pesquisa
1.
A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
Mol Cancer
; 12(1): 128, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24156782
2.
The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Cancer Sci
; 103(3): 522-7, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22181674
3.
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Nat Commun
; 12(1): 3636, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140467
4.
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Br J Haematol
; 150(1): 46-57, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20507304
5.
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
J Med Chem
; 48(2): 414-26, 2005 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-15658855
6.
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
ACS Med Chem Lett
; 6(7): 798-803, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26191369
7.
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Mol Cancer Ther
; 11(8): 1799-808, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22714264
8.
Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Cell Cycle
; 8(12): 1921-9, 2009 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19440047
9.
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
J Med Chem
; 52(2): 379-88, 2009 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-19143567
10.
Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma.
J Gene Med
; 5(5): 407-16, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12731089